Overview

ANAVEX2-73 Study in Patients With Rett Syndrome

Status:
Recruiting

Trial end date:
2021-09-01

Target enrollment:

Participant gender:

Summary

ANAVEX2-73-RS-002 is a Phase 2, double-blind, randomized, placebo-controlled dose escalation safety, tolerability and efficacy study in patients 18 years and older with RTT using endpoints including multiple clinical and exploratory molecular and biochemical measures.

Phase:

Phase 2

Details

Lead Sponsor:

Anavex Life Sciences Corp.

Treatments:

Pharmaceutical Solutions